Synergistically Enhanced Inhibitory Effects of Pullulan Nanoparticle-Mediated Co-Delivery of Lovastatin and Doxorubicin to Triple-Negative Breast Cancer Cells

Overview

Journal Nanoscale Res Lett

Publisher Springer

Specialty Biotechnology

Date 2019 Sep 15

PMID 31520223

Citations 5

Authors

Di Wu

Yao Chen

Shun Wen

Yi Wen

Rong Wang

Qiuting Zhang

Ge Qin

Huimei Yi

Mi Wu

Lu Lu

Xiaojun Tao

Xiyun Deng

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is prone to drug resistance and difficult to treat. In this study, we grafted water-soluble pullulan with lovastatin (LV) to develop a novel amphiphilic conjugate, pullulan-encapsulated LV (PLV). The PLV conjugate was synthesized with three different ratios of pullulan to LV and characterized by Fourier transform infrared (FTIR). The degree of substitution (DS) of LV in terms of molar ratio was 7.87%, 3.58%, and 3.06% for PLV (1/2), PLV (1/3), and PLV (1/4), respectively, by proton NMR analysis. We selected the PLV (1/2) conjugate to prepare doxorubicin (DXR)-loaded PLV nanoparticles (PLV/DXR NPs) because of its superior properties. The average size and zeta potential for PLV (1/2) NPs were 177.6 nm and - 11.66 mV, respectively, determined by dynamic light scattering, and those for PLV/DXR NPs were 225.6 nm and - 10.51 mV, respectively. In vitro drug release profiling showed that PLV/DXR NPs sustainably released DXR within 72 h, which was more robust at pH 5.4 (97.90%) than pH 7.4 (76.15%). In the cytotoxicity study, PLV/DXR NPs showed greater inhibition of proliferation of TNBC MDA-MB-231 than non-TNBC MDA-MB-453 cells (IC 0.60 vs 11.05 μM). FITC-loaded PLV/DXR NPs were prepared to investigate cellular uptake: both cell lines showed a time-dependent uptake of NPs, but the number of NPs entering MDA-MB-231 cells was greater than that entering the MDA-MB-453 cells. Pullulan-based NP co-delivery of LV and DXR could efficiently inhibit TNBC cells, which may help in designing a powerful drug delivery system for treating TNBC.

Citing Articles

Potential of Pullulan-Based Polymeric Nanoparticles for Improving Drug Physicochemical Properties and Effectiveness.

Thomas N, Puluhulawa L, Cindana Moo F, Rusdin A, Gazzali A, Budiman A Polymers (Basel). 2024; 16(15).

PMID: 39125177 PMC: 11313896. DOI: 10.3390/polym16152151.

Lipid-based nanoparticle-mediated combination therapy for breast cancer management: a comprehensive review.

Gupta P, Neupane Y, Aqil M, Kohli K, Sultana Y Drug Deliv Transl Res. 2023; 13(11):2739-2766.

PMID: 37261602 DOI: 10.1007/s13346-023-01366-z.

Inhibitory effect of lovastatin on human lung cancer cell proliferation by regulating the ERK1/2 and COX-2 pathways.

Liu S, Yang P, Wang M, Zhang S, Wang J, Pan T Transl Cancer Res. 2022; 11(4):813-822.

PMID: 35571660 PMC: 9091021. DOI: 10.21037/tcr-22-346.

Anti-tumor activity of resveratrol against gastric cancer: a review of recent advances with an emphasis on molecular pathways.

Ashrafizadeh M, Rafiei H, Mohammadinejad R, Farkhondeh T, Samarghandian S Cancer Cell Int. 2021; 21(1):66.

PMID: 33478512 PMC: 7818776. DOI: 10.1186/s12935-021-01773-7.

Synergistic antitumor effect of 5-fluorouracil and withaferin-A induces endoplasmic reticulum stress-mediated autophagy and apoptosis in colorectal cancer cells.

Alnuqaydan A, Rah B, Almutary A, Chauhan S Am J Cancer Res. 2020; 10(3):799-815.

PMID: 32266092 PMC: 7136917.

References

Dimitroulakos J, Ye L, Benzaquen M, Moore M, Kamel-Reid S, Freedman M . Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res. 2001; 7(1):158-67. View

Holstein S, Hohl R . Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk Res. 2001; 25(8):651-60. DOI: 10.1016/s0145-2126(00)00162-4. View

Wang E, Casciano C, Clement R, Johnson W . HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001; 18(6):800-6. DOI: 10.1023/a:1011036428972. View

Tobert J . Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003; 2(7):517-26. DOI: 10.1038/nrd1112. View

Campbell M, Esserman L, Zhou Y, Shoemaker M, Lobo M, Borman E . Breast cancer growth prevention by statins. Cancer Res. 2006; 66(17):8707-14. DOI: 10.1158/0008-5472.CAN-05-4061. View

Nofech-Mozes S, Trudeau M, Kahn H, Dent R, Rawlinson E, Sun P . Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat. 2009; 118(1):131-7. DOI: 10.1007/s10549-008-0295-8. View

Ganta S, Amiji M . Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm. 2009; 6(3):928-39. DOI: 10.1021/mp800240j. View

Lehar J, Krueger A, Avery W, Heilbut A, Johansen L, Price E . Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009; 27(7):659-66. PMC: 2708317. DOI: 10.1038/nbt.1549. View

Martirosyan A, Clendening J, Goard C, Penn L . Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer. 2010; 10:103. PMC: 2847546. DOI: 10.1186/1471-2407-10-103. View

10.

Torchilin V . Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2010; 63(3):131-5. DOI: 10.1016/j.addr.2010.03.011. View

11.

Fan L, Li F, Zhang H, Wang Y, Cheng C, Li X . Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials. 2010; 31(21):5634-42. DOI: 10.1016/j.biomaterials.2010.03.066. View

12.

Maeda H, Matsumura Y . EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Adv Drug Deliv Rev. 2010; 63(3):129-30. DOI: 10.1016/j.addr.2010.05.001. View

13.

Aryal S, Hu C, Zhang L . Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small. 2010; 6(13):1442-8. DOI: 10.1002/smll.201000631. View

14.

Acharya S, Sahoo S . PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2010; 63(3):170-83. DOI: 10.1016/j.addr.2010.10.008. View

15.

Goard C, Mather R, Vinepal B, Clendening J, Martirosyan A, Boutros P . Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. Int J Cancer. 2011; 127(12):2936-48. DOI: 10.1002/ijc.25295. View

16.

Tallarida R . Revisiting the isobole and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther. 2012; 342(1):2-8. PMC: 3383036. DOI: 10.1124/jpet.112.193474. View

17.

Tallarida R . Quantitative methods for assessing drug synergism. Genes Cancer. 2012; 2(11):1003-8. PMC: 3379564. DOI: 10.1177/1947601912440575. View

18.

Duan X, Xiao J, Yin Q, Zhang Z, Yu H, Mao S . Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano. 2013; 7(7):5858-69. DOI: 10.1021/nn4010796. View

19.

Liu J, Huang Y, Kumar A, Tan A, Jin S, Mozhi A . pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv. 2013; 32(4):693-710. DOI: 10.1016/j.biotechadv.2013.11.009. View

20.

Guo S, Lin C, Xu Z, Miao L, Wang Y, Huang L . Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano. 2014; 8(5):4996-5009. PMC: 4046782. DOI: 10.1021/nn5010815. View